Raynaud's Phenomenon (RP) results from exaggerated cold-induced vasoconstriction. RP patients suffer from vasospastic attacks and compromised digital blood perfusion leading to a triple color change at the level the fingers. Severe RP may cause ulcers and threaten tissue viability. Many drugs have been used to alleviate the symptoms of RP. These include calcium-channel blockers, cGMP-specific phosphodiesterase type 5 inhibitors, prostacyclin analogs, and angiotensin receptor blockers. Despite their variety, these drugs do not treat RP but rather alleviate its symptoms. To date, no drug for RP has been yet approved by the U.S Food and Drugs Administration. Cilostazol is a selective inhibitor of phosphodiesterase-III, originally prescribed to treat intermittent claudication. Owing to its antiplatelet and vasodilating properties, cilostazol is being repurposed as a potential drug for RP. This review focuses on the different lines of action of cilostazol serving to enhance blood perfusion in RP patients.

雷诺现象（RP）是由过大的感冒诱发的血管收缩引起的。RP患者患有血管痉挛发作和数字血液灌注受损，导致手指水平出现三重颜色变化。严重的RP可能会引起溃疡并威胁组织的生存能力。已经使用许多药物来减轻RP的症状。这些药物包括钙通道阻滞剂，cGMP特异性5型磷酸二酯酶抑制剂，前列环素类似物和血管紧张素受体阻滞剂。尽管种类繁多，但这些药物不能治疗RP，而是可以缓解其症状。迄今为止，尚未有美国食品和药物管理局批准用于RP的药物。西洛他唑是磷酸二酯酶III的选择性抑制剂，最初被指定用于治疗间歇性lau行。由于其抗血小板和血管舒张特性，西洛他唑正被重新定位为潜在的RP药物。这篇综述着重于西洛他唑用于增强RP患者血液灌注的不同作用方式。